📊 TCBIO Key Takeaways
Is Texas Capital Bancshares Inc./Tx (TCBIO) a Good Investment?
Strong revenue growth of 72% demonstrates market expansion, but severe margin compression—with net income growing only 5.5%—indicates operational challenges or acquisition integration costs. Conservative balance sheet and robust cash flow ($347.6M FCF) provide stability, yet low interest coverage (1.1x) and moderate ROE (9.1%) raise profitability quality concerns.
Why Buy Texas Capital Bancshares Inc./Tx Stock? TCBIO Key Strengths
- Exceptional revenue growth of 72.2% YoY indicates strong market demand or successful expansion
- Strong free cash flow generation of $347.6M with 19.6% FCF margin demonstrates cash conversion ability
- Conservative capital structure with debt-to-equity of 0.17x provides financial flexibility and low default risk
TCBIO Stock Risks: Texas Capital Bancshares Inc./Tx Investment Risks
- Severe earnings margin compression with revenue up 72% but net income up only 5.5% signals operational stress or integration challenges
- Critically low interest coverage ratio of 1.1x raises concerns about debt service sustainability for a financial institution
- Moderate ROE of 9.1% and ROA of 1.0% suggest suboptimal capital efficiency despite strong growth
Key Metrics to Watch
- Net margin trend and operating expense ratio control—critical to validate profitability sustainability
- Interest coverage ratio improvement—must move above 2.0x for financial health
- Return on equity trajectory—target minimum 12%+ for competitive industry positioning
Texas Capital Bancshares Inc./Tx (TCBIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
TCBIO Profit Margin, ROE & Profitability Analysis
TCBIO vs Finance Sector: How Texas Capital Bancshares Inc./Tx Compares
How Texas Capital Bancshares Inc./Tx compares to Finance sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Texas Capital Bancshares Inc./Tx Stock Overvalued? TCBIO Valuation Analysis 2026
Based on fundamental analysis, Texas Capital Bancshares Inc./Tx has mixed fundamental signals relative to the Finance sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Texas Capital Bancshares Inc./Tx Balance Sheet: TCBIO Debt, Cash & Liquidity
TCBIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Texas Capital Bancshares Inc./Tx's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $3.54 reflects profitable operations.
TCBIO Revenue Growth, EPS Growth & YoY Performance
Texas Capital Bancshares Inc./Tx Dividends, Buybacks & Capital Allocation
TCBIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Texas Capital Bancshares Inc./Tx (CIK: 0001077428)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TCBIO
What is the AI rating for TCBIO?
Texas Capital Bancshares Inc./Tx (TCBIO) has an AI rating of HOLD with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TCBIO's key strengths?
Claude: Exceptional revenue growth of 72.2% YoY indicates strong market demand or successful expansion. Strong free cash flow generation of $347.6M with 19.6% FCF margin demonstrates cash conversion ability.
What are the risks of investing in TCBIO?
Claude: Severe earnings margin compression with revenue up 72% but net income up only 5.5% signals operational stress or integration challenges. Critically low interest coverage ratio of 1.1x raises concerns about debt service sustainability for a financial institution.
What is TCBIO's revenue and growth?
Texas Capital Bancshares Inc./Tx reported revenue of $1.8B.
Does TCBIO pay dividends?
Texas Capital Bancshares Inc./Tx does not currently pay dividends.
Where can I find TCBIO SEC filings?
Official SEC filings for Texas Capital Bancshares Inc./Tx (CIK: 0001077428) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TCBIO's EPS?
Texas Capital Bancshares Inc./Tx has a diluted EPS of $6.79.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TCBIO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Texas Capital Bancshares Inc./Tx has a HOLD rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TCBIO stock overvalued or undervalued?
Valuation metrics for TCBIO: ROE of 9.1% (sector avg: 12%), net margin of 18.6% (sector avg: 25%). Compare these metrics with sector averages to assess valuation.
Should I buy TCBIO stock in 2026?
Our dual AI analysis gives Texas Capital Bancshares Inc./Tx a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TCBIO's free cash flow?
Texas Capital Bancshares Inc./Tx's operating cash flow is $360.2M, with capital expenditures of $12.6M. FCF margin is 19.6%.
How does TCBIO compare to other Finance stocks?
Vs Finance sector averages: Net margin 18.6% (avg: 25%), ROE 9.1% (avg: 12%), current ratio N/A (avg: 1.2).